E November Marijuana Market Performance Sliced & Diced By Segment
Article By:
Lorimer Wilson
Read
Thursday, December 5, 2019 4:42 AM EST
Every month I slice and dice the performance of 6 categories within the overall cannabis market to unveil the strengths and weaknesses of its components and November saw a dramatic spread in the returns of those categories
Huge Biotech M&A Premiums Narrow Perception Gap
Article By:
Lipper Alpha Insight
Read
Wednesday, December 4, 2019 6:27 AM EST
The premiums needed to seal biotechnology acquisitions have always been high, but they’ve reached the stratosphere this year
E Pitfalls Of Biotechnology Investing
Article By:
Ketan Desai
Read
Tuesday, December 3, 2019 4:53 PM EST
How capital distorts the availability of biotechnology companies.
In this article: IBB
Canopy Growth (CGC) Bull Flag Forming
Article By:
Gareth Soloway
Read
Monday, December 2, 2019 1:48 PM EST
Shares of marijuana player Canopy Growth continue to trade sideways to lower after an over 50% surge just a couple weeks ago.
In this article: CGC
E November Performance Of The Market's 15 Cannabis ETFs Ranged From +6.1% To -14.4%
Article By:
Lorimer Wilson
Read
Monday, December 2, 2019 4:36 AM EST
The performance of the 15 marijuana/marijuana-related ETFs varies depending on their constituents. In November this segment of the cannabis market ranged from +6.1% to -14.4% (excluding the 2 leveraged ETFs) and declined, on average, 7.3% in total.
8 Monster Stock Market Predictions For The Week Of December 2
Article By:
Michael J. Kramer
Read
Sunday, December 1, 2019 11:49 AM EST
It will be a busy week for economic data with the ISM reports and plenty of job data likely going to decide which way the markets go. But then again, the market knows weak data will force the Fed’s hand to take action.
Week In Review: Pharmaron, A Beijing CRO, Stages $434 Million Hong Kong IPO
Article By:
ChinaBio® Today
Read
Saturday, November 30, 2019 4:07 PM EST
Pharmaron Beijing staged a $434 million Hong Kong IPO to expand its international CRO operations. In January, Pharmaron completed a $76 million IPO on the Shenzhen Exchange, and its stock price has quadrupled since its debut.
In this article: MRK
2 Names To Consider In A Heating Up Small-Cap Biotech Sector
Article By:
Scott Matusow
Read
Wednesday, November 27, 2019 8:30 AM EST
The biotech sector has been heating up due to an increased risk appetite coming from additional market liquidity and a favorable Fed policy. Here, we highlight 2 early-stage biotech companies that we think can provide substantial upside.
Here Is The 14th Most Popular Stock Among 752 Hedge Funds
Article By:
Insider Monkey
Read
Sunday, November 24, 2019 11:24 PM EST
Is Netflix a buy right now? The number of bullish hedge fund bets went down by 11 in recent months. Nevertheless our calculations also showed that NFLX ranked 14th among the 30 most popular stocks among hedge funds.
E Wither Flexion?
Article By:
Ketan Desai
Read
Sunday, November 24, 2019 1:13 PM EST
A new study highlights that there are likely fewer candidates for Flexion's star osteoarthritis treatment and this could affect the stock price of Flexion considerably.
In this article: FLXN
Week In Review: Fosun Pharma Acquires Brain Cancer Immunotherapy In $148 Million Deal
Article By:
ChinaBio® Today
Read
Saturday, November 23, 2019 4:26 PM EST
Shanghai Fosun Pharma announced a $148 million agreement to acquire China rights for SurVaxM, a novel immunotherapy aimed at glioblastoma, from MimiVax of Buffalo, New York.
In this article: NVS
Aslan Soars 186% After Journal Reports New Acute Myeloid Leukemia Data
Article By:
The Fly
Read
Saturday, November 23, 2019 11:10 AM EST
Aslan Pharmaceuticals announced that new preclinical data characterizing ASLAN003 as a potential treatment for acute myeloid leukemia has been published in the November issue of Haematologica Journal which sent shares surging higher.
In this article: ASLN
E U.S. House Committee Clears Bill On Federal Cannabis Legalization - Pot Stocks Soar
Article By:
Lorimer Wilson
Read
Thursday, November 21, 2019 11:10 PM EST
If the MORE bill passes, it will end federal cannabis prohibition.
Crispr Therapeutics Trade Review: How We Scored A Huge 24% Gain In Just 2 Days
Article By:
Deron Wagner
Read
Thursday, November 21, 2019 12:25 PM EST
We recently locked in a cool gain of +24% with a 2-day swing trade in Crispr Therapeutics (CRSP). Continue reading this educational trade walk-through to find out exactly how we did it.
In this article: CRSP